InFlectis BioScience

InFlectis BioScience SAS is a biopharmaceutical company headquartered in Nantes, France, specializing in the discovery and development of small molecule drugs for the treatment of protein misfolding diseases. The company plans to demonstrate the clinical efficacy of its candidate IFB-088 in humans and then partner with a pharmaceutical organization for subsequent development and commercialization. Meanwhile, InFlectis continues to develop new chemical series for the treatment of non-orphan diseases, whose etiology also lies in the accumulation of misfolded proteins.